Pharmaron Beijing Co., Ltd. (Stock Code: 03759) submitted a monthly update to the Hong Kong Exchanges and Clearing Limited for the period ended 28 February 2026, with the submission date on 04 March 2026.

Pharmaron’s total authorised share capital stood at 1.84 billion shares. Within this structure, H shares remained at 359.98 million, and A shares (listed in Shenzhen) remained at 1.48 billion. There was no change in the volume of either H or A shares during the reporting month.

The outstanding issued H shares totaled 352.71 million at the end of February, while 7.26 million H shares were held in treasury. These treasury H shares remain designated under the “2025 H Share Award and Trust Scheme,” which was initially approved in June 2025.

Pharmaron’s public float requirements for its H shares, as stipulated in the relevant listing rules, remained in compliance during February. No new share issuance or treasury share transfers occurred, and the share incentive plans for A shares, previously approved by the board, did not result in any additional share issuances or transfers. All essential confirmation requirements were met with no noted irregularities.